Key result
Current guidelines recommend universal HCV screening during each pregnancy, with ongoing focus on the safety and efficacy of direct-acting antiviral initiation during pregnancy and postpartum care.
This review highlights the importance of universal HCV screening during pregnancy and discusses emerging evidence on DAA treatment and postpartum linkage to care.
Supports universal prenatal HCV screening; leaves open optimal DAA timing and postpartum care pending further data.
OBJECTIVE: The rising prevalence of hepatitis C infections among individuals of reproductive age further emphasizes the importance of evidence-based management of hepatitis C virus (HCV) during pregnancy to minimize perinatal transmission and to optimize maternal and fetal outcomes. In this review, we discuss the most recent recommendations on the management of HCV in pregnancy, including recommendations for screening and treatment during pregnancy and the postpartum period, as well as infant management to reduce perinatal transmission of HCV. RECENT FINDINGS: Current guidelines recommend universal HCV screening during each pregnancy. With varying guidance regarding the use of direct-acting antivirals (DAAs) during pregnancy, recent studies have focused on the safety and efficacy of DAA initiation during pregnancy. Additionally, there has been an increased focus on improving treatment rates in the postpartum period through innovative linkage to care efforts, telemedicine, and additional efforts reducing barriers to care for patients.
No takes yet. Share an insight, caveat, or question.
Rios et al. (2024) conducted a review in Hepatitis C in pregnancy. Hepatitis C screening and management was evaluated. Current guidelines recommend universal HCV screening during each pregnancy, with ongoing focus on the safety and efficacy of direct-acting antiviral initiation during pregnancy and postpartum care.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: